Caterpillar Crushes Earnings Views, But Light Sales Dent Dow Jones Heavyweight
Caterpillar earnings muscled past estimates, but sales dipped from a year ago. Profit margins expanded but the Dow Jones stock slipped.
You won't believe the amount of money that the bottler intends to return to shareholders.
Palantir followed up its “bombastic” December quarter with even better results for the March quarter as the data analytics software company continued to gain traction with its artificial-intelligence tools, in particular with U.S. commercial customers. Palantir shares, which rallied 8.1% in Monday’s regular session, were down more than 14% to $21.56 in midday trading Tuesday. For the March quarter, Palantir posted revenue of $634 million, up 21% from a year ago, and ahead of both the company’s guidance range of $612 million to $616 million and Wall Street’s consensus of $615 million as tracked by FactSet.
Prepare yourself for a big shock.
Over the past six years, billionaire Bill Gates has spent more than $113 million purchasing Nebraska farmland and has taken out two loans totaling $700 million against it. Gates owns about 20,000 acres of farmland in Nebraska, where longtime friend and fellow billionaire Warren Buffett resides. The farmland is held by more than 20 shell companies. Why would one of the world's richest people need to take out a loan? Many high-net-worth individuals borrow against their assets if they need money th
Warren Buffett is selling his largest holding, and that's a huge deal.
Lower realizations of commodity prices hurt BP's earnings in Q1.
After a rocky month of April, investor sentiment has improved somewhat. At least in part, this can be attributed to a better-than-expected earnings season. So far, about 80% of the S&P 500-listed companies have reported their Q1 results, and 77% of those have shown a quarterly EPS above the forecasts. Overall, the earnings reported are 7.5% better than the estimates, a beat that’s well above the 6.7% decadal average. Scott Chronert, a U.S. equity strategist at Citigroup, comments on the broader
On CRISPR Therapeutics' (CRSP) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to the first sales numbers of its newly approved gene therapy, Casgevy.
The industrial giant has taken the right actions in cutting its dividend and clarifying its legal issues, and it is now fully in restructuring mode.
Investors holding Nvidia continue to check to see what others in the market are doing. The reason: Even with obvious market leaders like Nvidia stock, it can be challenging to make trading decisions. One answer came Tuesday from billionaire investor Stanley Druckenmiller.